Zobrazit v EDS

Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Uloženo v:
Podrobná bibliografie
Název: Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Autoři: Palmer, Daniel H., Jackson, Richard, Springfeld, Christoph, Ghaneh, Paula, Rawcliffe, Charlotte, Halloran, Christopher M., Faluyi, Olusola, Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Ma, Yuk Ting, Middleton, Gary William, Cummins, Sebastian, Ross, Paul J., Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Hammel, Pascal, Borg, David, Sothi, Sharmila, Valle, Juan W., Mehrabi, Arianeb, Bailey, Peter, Tjaden, Christine, Michalski, Christoph, Hackert, Thilo, Büchler, Markus W., Neoptolemos, John P.
Přispěvatelé: Lund University, Profile areas and other strong research environments, Other Strong Research Environments, LUCC: Lund University Cancer Centre, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Övriga starka forskningsmiljöer, LUCC: Lunds universitets cancercentrum, Originator, Lund University, Faculty of Medicine, Department of Clinical Sciences, Lund, Section I, Therapeutic pathology, Lunds universitet, Medicinska fakulteten, Institutionen för kliniska vetenskaper, Lund, Sektion I, Terapeutisk patologi, Originator
Zdroj: Journal of Clinical Oncology. 43(10):1240-1253
Témata: Medical and Health Sciences, Clinical Medicine, Surgery, Medicin och hälsovetenskap, Klinisk medicin, Kirurgi, Cancer and Oncology, Cancer och onkologi
Popis: PURPOSE The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival for modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) than gemcitabine but had more restrictive eligibility criteria. Our aim was to analyze the ESPAC4 survival on long-Term follow-up. METHODS The OS of 732 ESPAC4 patients comparing 367 randomly assigned to gemcitabine and 365 to GemCap was previously reported after a median follow-up time of 43.2 months (95% CI, 39.7 to 45.5) and 458 deaths. Analysis was now carried out after a median follow-up of 104 months (101-108) and 566 deaths. RESULTS The median OS was 29.5 months (27.5-32.1) for all patients, 28.4 months (25.2-32.0) in the gemcitabine group and 31.6 months (26.5-38.0) in the GemCap group (hazard ratio [HR], 0.83 [0.71 to 0.98]; P =.031). R0 patients given gemcitabine had a median survival of 32.2 months (27.9-41.6) compared with 49.9 months (39.0-82.3) for those given GemCap (HR, 0.63 [0.47 to 0.84]; P =.002). Lymph node-negative patients had significantly higher 5 year OS rates on GemCap (59% [49%-71%]) than gemcitabine (53% [42%-66%]; HR, 0.63 [0.41 to 0.98]; P =.04) but not those with positive lymph nodes (P =.225). The OS advantage for GemCap was retained in the PRODIGE24 subgroup of 193 (26.4%) ESPAC4 patients not eligible for PRODIGE24 with a median survival of 20.7 (16.2-27.3) months in patients allocated to gemcitabine compared with 25.9 (22.3-30.2) months for ineligible patients allocated to GemCap (HR, 0.71 [95% CI, 0.52 to 0.98]; χ2log-rank-1df = 4.31; P =.038). CONCLUSION GemCap is a standard option for patients not eligible for mFOLFIRINOX. Exploratory evidence suggests that GemCap may be particularly efficacious in R0 patients and also in lymph node-negative patients.
Přístupová URL adresa: https://doi.org/10.1200/JCO.24.01118
Databáze: SwePub
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://doi.org/10.1200/JCO.24.01118#
    Name: EDS - SwePub (s4221598)
    Category: fullText
    Text: View record in SwePub
  – Url: https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=EBSCO&SrcAuth=EBSCO&DestApp=WOS&ServiceName=TransferToWoS&DestLinkType=GeneralSearchSummary&Func=Links&author=Palmer%20DH
    Name: ISI
    Category: fullText
    Text: Nájsť tento článok vo Web of Science
    Icon: https://imagesrvr.epnet.com/ls/20docs.gif
    MouseOverText: Nájsť tento článok vo Web of Science
Header DbId: edsswe
DbLabel: SwePub
An: edsswe.oai.portal.research.lu.se.publications.2d2ad34d.7ab7.48ec.b1bb.1156098a9327
RelevancyScore: 1132
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 1132.48608398438
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Palmer%2C+Daniel+H%2E%22">Palmer, Daniel H.</searchLink><br /><searchLink fieldCode="AR" term="%22Jackson%2C+Richard%22">Jackson, Richard</searchLink><br /><searchLink fieldCode="AR" term="%22Springfeld%2C+Christoph%22">Springfeld, Christoph</searchLink><br /><searchLink fieldCode="AR" term="%22Ghaneh%2C+Paula%22">Ghaneh, Paula</searchLink><br /><searchLink fieldCode="AR" term="%22Rawcliffe%2C+Charlotte%22">Rawcliffe, Charlotte</searchLink><br /><searchLink fieldCode="AR" term="%22Halloran%2C+Christopher+M%2E%22">Halloran, Christopher M.</searchLink><br /><searchLink fieldCode="AR" term="%22Faluyi%2C+Olusola%22">Faluyi, Olusola</searchLink><br /><searchLink fieldCode="AR" term="%22Cunningham%2C+David%22">Cunningham, David</searchLink><br /><searchLink fieldCode="AR" term="%22Wadsley%2C+Jonathan%22">Wadsley, Jonathan</searchLink><br /><searchLink fieldCode="AR" term="%22Darby%2C+Suzanne%22">Darby, Suzanne</searchLink><br /><searchLink fieldCode="AR" term="%22Meyer%2C+Tim%22">Meyer, Tim</searchLink><br /><searchLink fieldCode="AR" term="%22Gillmore%2C+Roopinder%22">Gillmore, Roopinder</searchLink><br /><searchLink fieldCode="AR" term="%22Lind%2C+Pehr%22">Lind, Pehr</searchLink><br /><searchLink fieldCode="AR" term="%22Glimelius%2C+Bengt%22">Glimelius, Bengt</searchLink><br /><searchLink fieldCode="AR" term="%22Falk%2C+Stephen%22">Falk, Stephen</searchLink><br /><searchLink fieldCode="AR" term="%22Ma%2C+Yuk+Ting%22">Ma, Yuk Ting</searchLink><br /><searchLink fieldCode="AR" term="%22Middleton%2C+Gary+William%22">Middleton, Gary William</searchLink><br /><searchLink fieldCode="AR" term="%22Cummins%2C+Sebastian%22">Cummins, Sebastian</searchLink><br /><searchLink fieldCode="AR" term="%22Ross%2C+Paul+J%2E%22">Ross, Paul J.</searchLink><br /><searchLink fieldCode="AR" term="%22Wasan%2C+Harpreet%22">Wasan, Harpreet</searchLink><br /><searchLink fieldCode="AR" term="%22McDonald%2C+Alec%22">McDonald, Alec</searchLink><br /><searchLink fieldCode="AR" term="%22Crosby%2C+Tom%22">Crosby, Tom</searchLink><br /><searchLink fieldCode="AR" term="%22Hammel%2C+Pascal%22">Hammel, Pascal</searchLink><br /><searchLink fieldCode="AR" term="%22Borg%2C+David%22">Borg, David</searchLink><br /><searchLink fieldCode="AR" term="%22Sothi%2C+Sharmila%22">Sothi, Sharmila</searchLink><br /><searchLink fieldCode="AR" term="%22Valle%2C+Juan+W%2E%22">Valle, Juan W.</searchLink><br /><searchLink fieldCode="AR" term="%22Mehrabi%2C+Arianeb%22">Mehrabi, Arianeb</searchLink><br /><searchLink fieldCode="AR" term="%22Bailey%2C+Peter%22">Bailey, Peter</searchLink><br /><searchLink fieldCode="AR" term="%22Tjaden%2C+Christine%22">Tjaden, Christine</searchLink><br /><searchLink fieldCode="AR" term="%22Michalski%2C+Christoph%22">Michalski, Christoph</searchLink><br /><searchLink fieldCode="AR" term="%22Hackert%2C+Thilo%22">Hackert, Thilo</searchLink><br /><searchLink fieldCode="AR" term="%22Büchler%2C+Markus+W%2E%22">Büchler, Markus W.</searchLink><br /><searchLink fieldCode="AR" term="%22Neoptolemos%2C+John+P%2E%22">Neoptolemos, John P.</searchLink>
– Name: Author
  Label: Contributors
  Group: Au
  Data: Lund University, Profile areas and other strong research environments, Other Strong Research Environments, LUCC: Lund University Cancer Centre, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Övriga starka forskningsmiljöer, LUCC: Lunds universitets cancercentrum, Originator<br />Lund University, Faculty of Medicine, Department of Clinical Sciences, Lund, Section I, Therapeutic pathology, Lunds universitet, Medicinska fakulteten, Institutionen för kliniska vetenskaper, Lund, Sektion I, Terapeutisk patologi, Originator
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <i>Journal of Clinical Oncology</i>. 43(10):1240-1253
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Medical+and+Health+Sciences%22">Medical and Health Sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+Medicine%22">Clinical Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Surgery%22">Surgery</searchLink><br /><searchLink fieldCode="DE" term="%22Medicin+och+hälsovetenskap%22">Medicin och hälsovetenskap</searchLink><br /><searchLink fieldCode="DE" term="%22Klinisk+medicin%22">Klinisk medicin</searchLink><br /><searchLink fieldCode="DE" term="%22Kirurgi%22">Kirurgi</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+and+Oncology%22">Cancer and Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+och+onkologi%22">Cancer och onkologi</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: PURPOSE The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival for modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) than gemcitabine but had more restrictive eligibility criteria. Our aim was to analyze the ESPAC4 survival on long-Term follow-up. METHODS The OS of 732 ESPAC4 patients comparing 367 randomly assigned to gemcitabine and 365 to GemCap was previously reported after a median follow-up time of 43.2 months (95% CI, 39.7 to 45.5) and 458 deaths. Analysis was now carried out after a median follow-up of 104 months (101-108) and 566 deaths. RESULTS The median OS was 29.5 months (27.5-32.1) for all patients, 28.4 months (25.2-32.0) in the gemcitabine group and 31.6 months (26.5-38.0) in the GemCap group (hazard ratio [HR], 0.83 [0.71 to 0.98]; P =.031). R0 patients given gemcitabine had a median survival of 32.2 months (27.9-41.6) compared with 49.9 months (39.0-82.3) for those given GemCap (HR, 0.63 [0.47 to 0.84]; P =.002). Lymph node-negative patients had significantly higher 5 year OS rates on GemCap (59% [49%-71%]) than gemcitabine (53% [42%-66%]; HR, 0.63 [0.41 to 0.98]; P =.04) but not those with positive lymph nodes (P =.225). The OS advantage for GemCap was retained in the PRODIGE24 subgroup of 193 (26.4%) ESPAC4 patients not eligible for PRODIGE24 with a median survival of 20.7 (16.2-27.3) months in patients allocated to gemcitabine compared with 25.9 (22.3-30.2) months for ineligible patients allocated to GemCap (HR, 0.71 [95% CI, 0.52 to 0.98]; χ2log-rank-1df = 4.31; P =.038). CONCLUSION GemCap is a standard option for patients not eligible for mFOLFIRINOX. Exploratory evidence suggests that GemCap may be particularly efficacious in R0 patients and also in lymph node-negative patients.
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doi.org/10.1200/JCO.24.01118" linkWindow="_blank">https://doi.org/10.1200/JCO.24.01118</link>
PLink https://erproxy.cvtisr.sk/sfx/access?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsswe&AN=edsswe.oai.portal.research.lu.se.publications.2d2ad34d.7ab7.48ec.b1bb.1156098a9327
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO.24.01118
    Languages:
      – Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 14
        StartPage: 1240
    Subjects:
      – SubjectFull: Medical and Health Sciences
        Type: general
      – SubjectFull: Clinical Medicine
        Type: general
      – SubjectFull: Surgery
        Type: general
      – SubjectFull: Medicin och hälsovetenskap
        Type: general
      – SubjectFull: Klinisk medicin
        Type: general
      – SubjectFull: Kirurgi
        Type: general
      – SubjectFull: Cancer and Oncology
        Type: general
      – SubjectFull: Cancer och onkologi
        Type: general
    Titles:
      – TitleFull: Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Palmer, Daniel H.
      – PersonEntity:
          Name:
            NameFull: Jackson, Richard
      – PersonEntity:
          Name:
            NameFull: Springfeld, Christoph
      – PersonEntity:
          Name:
            NameFull: Ghaneh, Paula
      – PersonEntity:
          Name:
            NameFull: Rawcliffe, Charlotte
      – PersonEntity:
          Name:
            NameFull: Halloran, Christopher M.
      – PersonEntity:
          Name:
            NameFull: Faluyi, Olusola
      – PersonEntity:
          Name:
            NameFull: Cunningham, David
      – PersonEntity:
          Name:
            NameFull: Wadsley, Jonathan
      – PersonEntity:
          Name:
            NameFull: Darby, Suzanne
      – PersonEntity:
          Name:
            NameFull: Meyer, Tim
      – PersonEntity:
          Name:
            NameFull: Gillmore, Roopinder
      – PersonEntity:
          Name:
            NameFull: Lind, Pehr
      – PersonEntity:
          Name:
            NameFull: Glimelius, Bengt
      – PersonEntity:
          Name:
            NameFull: Falk, Stephen
      – PersonEntity:
          Name:
            NameFull: Ma, Yuk Ting
      – PersonEntity:
          Name:
            NameFull: Middleton, Gary William
      – PersonEntity:
          Name:
            NameFull: Cummins, Sebastian
      – PersonEntity:
          Name:
            NameFull: Ross, Paul J.
      – PersonEntity:
          Name:
            NameFull: Wasan, Harpreet
      – PersonEntity:
          Name:
            NameFull: McDonald, Alec
      – PersonEntity:
          Name:
            NameFull: Crosby, Tom
      – PersonEntity:
          Name:
            NameFull: Hammel, Pascal
      – PersonEntity:
          Name:
            NameFull: Borg, David
      – PersonEntity:
          Name:
            NameFull: Sothi, Sharmila
      – PersonEntity:
          Name:
            NameFull: Valle, Juan W.
      – PersonEntity:
          Name:
            NameFull: Mehrabi, Arianeb
      – PersonEntity:
          Name:
            NameFull: Bailey, Peter
      – PersonEntity:
          Name:
            NameFull: Tjaden, Christine
      – PersonEntity:
          Name:
            NameFull: Michalski, Christoph
      – PersonEntity:
          Name:
            NameFull: Hackert, Thilo
      – PersonEntity:
          Name:
            NameFull: Büchler, Markus W.
      – PersonEntity:
          Name:
            NameFull: Neoptolemos, John P.
      – PersonEntity:
          Name:
            NameFull: Lund University, Profile areas and other strong research environments, Other Strong Research Environments, LUCC: Lund University Cancer Centre, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Övriga starka forskningsmiljöer, LUCC: Lunds universitets cancercentrum, Originator
      – PersonEntity:
          Name:
            NameFull: Lund University, Faculty of Medicine, Department of Clinical Sciences, Lund, Section I, Therapeutic pathology, Lunds universitet, Medicinska fakulteten, Institutionen för kliniska vetenskaper, Lund, Sektion I, Terapeutisk patologi, Originator
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 0732183X
            – Type: issn-print
              Value: 15277755
            – Type: issn-locals
              Value: SWEPUB_FREE
            – Type: issn-locals
              Value: LU_SWEPUB
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Journal of Clinical Oncology
              Type: main
ResultId 1